U.S. invests in domestic biotechnology manufacturing

The Department of Health and Human Services will invest $40 million to expand domestic manufacturing for active pharmaceutical ingredients, antibiotics and other essential medications, among other actions to support U.S. biotechnology and biomanufacturing, the agency announced today. The actions are part of a Sept. 12 executive order issued by President Biden to advance the U.S. bioeconomy.